Migrating into the Tumor: a Roadmap for T Cells

Trends in Cancer

Volumn 3, Issue 11, 2017, Pages 797-808

  van der Woude, Lieke L ^a,b   Gorris, Mark A J ^a   Halilovic, Altuna ^a,b   Figdor, Carl G ^a   de Vries, I Jolanda M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

biomarkers; immune cells; immunotherapy; migration; T cells; tumor microenvironment.

Indexed keywords

CHEMOKINE; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CELL SURVIVAL; CHEMOTAXIS; GRANULOCYTE; HUMAN; IMMUNE EVASION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; CELL MOTION; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; NEOPLASM; PATHOLOGY;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 85032281146     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2017.09.006     Document Type: Review

References (102)

1. Kerkar, S.P., Restifo, N.P., Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 72 (2012), 3125–3130.
2. Palucka, A.K., Coussens, L.M., The basis of oncoimmunology. Cell 164 (2016), 1233–1247.
3. Spranger, S., Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int. Immunol. 28 (2016), 383–391.
4. Gajewski, T.F., The next hurdle in cancer immunotherapy: overcoming the non-t-cell-inflamed tumor microenvironment. Semin. Oncol. 42 (2015), 663–671.
5. Hegde, P.S., et al. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res. 22 (2016), 1865–1874.
6. Fridman, W.H., et al. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12 (2012), 298–306.
7. Ji, R.R., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61 (2012), 1019–1031.
8. Tumeh, P.C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
9. Vasaturo, A., et al. T-cell landscape in a primary melanoma predicts the survival of patients with metastatic disease after their treatment with dendritic cell vaccines. Cancer Res. 76 (2016), 3496–3506.
10. Ager, A., et al. Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells. Biochem. Soc. Trans. 44 (2016), 377–385.
11. Woodland, D.L., Kohlmeier, J.E., Migration, maintenance and recall of memory T cells in peripheral tissues. Nat. Rev. Immunol. 9 (2009), 153–161.
12. Liu, J., et al. Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma. Oncotarget 6 (2015), 24978–24989.
13. Muthuswamy, R., et al. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells. Prostate 76 (2016), 1095–1105.
14. Mlecnik, B., et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 138 (2010), 1429–1440.
15. Berghuis, D., et al. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J. Pathol. 223 (2011), 347–357.
16. Andersson, A., et al. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J. Immunol. 182 (2009), 6951–6958.
17. Harlin, H., et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69 (2009), 3077–3085.
18. Chew, V., et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 61 (2012), 427–438.
19. Mikucki, M.E., et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat. Commun., 6, 2015, 7458.
20. Billottet, C., et al. CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochim. Biophys. Acta Rev. Cancer 1836 (2013), 287–295.
21. Fridlender, Z.G., CCL2 blockade augments cancer immunotherapy. Cancer Res., 70, 2010 2569–2569.
22. Feig, C., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 20212–20217.
23. Slaney, C.Y., et al. Trafficking of T cells into tumors. Cancer Res. 74 (2014), 7168–7174.
24. Mauldin, I.S., et al. Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. Cancer Immunol. Immunother. 65 (2016), 1189–1199.
25. Mauldin, I.S., et al. TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10. Int. J. Cancer 137 (2015), 1386–1396.
26. Molon, B., et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208 (2011), 1949–1962.
27. Peske, J.D., et al. Control of CD8 T-cell infiltration into tumors by vasculature and microenvironment. Adv. Cancer Res. 128 (2015), 263–307.
28. Bellone, M., Calcinotto, A., Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front. Oncol., 3, 2013, 231.
29. Motz, G.T., et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20 (2014), 607–615.
30. Jain, R.K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005), 58–62.
31. Huang, Y., et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 17561–17566.
32. Hodi, F.S., et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2 (2014), 632–642.
33. Robert, C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364 (2011), 2517–2526.
34. Wu, X., et al. VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma. Cancer Immunol. Res. 4 (2016), 858–868.
35. Wallin, J.J., et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun., 7, 2016, 12624.
36. Manegold, C., et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J. Thorac. Oncol. 12 (2017), 194–207.
37. Soto-Ortiz, L., Finley, S.D., Finley, A cancer treatment based on synergy between anti-angiogenic and immune cell therapies. J. Theor. Biol. 394 (2016), 197–211.
38. Singel, K.L., Segal, B.H., Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal. Immunol. Rev. 273 (2016), 329–343.
39. Eruslanov, E.B., et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J. Clin. Invest. 124 (2014), 5466–5480.
40. Singhal, S., et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell 30 (2016), 120–135.
41. Davis, B.P., Rothenberg, M.E., Eosinophils and cancer. Cancer Immunol. Res. 2 (2014), 1–8.
42. Carretero, R., et al. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat. Immunol. 16 (2015), 609–617.
43. Sektioglu, I.M., et al. Basophils promote tumor rejection via chemotaxis and infiltration of CD8+ T cells. Cancer Res. 77 (2017), 291–302.
44. Schutz, F., et al. PD-1/PD-L1 pathway in breast cancer. Oncol. Res. Treat. 40 (2017), 294–297.
45. Nomi, T., et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13 (2007), 2151–2157.
46. Konishi, J., et al. B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 10 (2004), 5094–5100.
47. Teng, M.W.L., et al. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 75 (2015), 2139–2145.
48. Ribas, A., Hu-Lieskovan, S., What does PD-L1 positive or negative mean?. J. Exp. Med. 213 (2016), 2835–2840.
49. Spranger, S., et al. Up-Regulation of PD-L1, IDO, and T-regs in the melanoma tumor microenvironment is driven by CD8(+) T Cells. Sci. Transl. Med., 5, 2013, 200ra116.
50. Spranger, S., et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J. Immunother. Cancer, 2, 2014, 3.
51. Peng, W.Y., et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 72 (2012), 5209–5218.
52. Kodumudi, K.N., et al. Immune checkpoint blockade to improve tumor infiltrating lymphocytes for adoptive cell therapy. PLoS One, 11, 2016, e0153053.
53. Patel, S.P., Kurzrock, R., PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14 (2015), 847–856.
54. Munn, D.H., Blocking IDO activity to enhance anti-tumor immunity. Front. Biosci. (Elite Ed.) 4 (2012), 734–745.
55. Prendergast, G.C., et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol. Immunother. 63 (2014), 721–735.
56. Holmgaard, R.B., et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. 13 (2015), 412–424.
57. Beatty, G.L., et al. First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies. Clin. Cancer Res. 23 (2017), 3269–3276.
58. Holmgaard, R.B., et al. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210 (2013), 1389–1402.
59. Spranger, S., et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J. Immunother. Cancer, 2, 2014, 3.
60. Hargadon, K.M., Dysregulation of TGF beta 1 activity in cancer and its influence on the quality of anti-tumor immunity. J. Clin. Med., 5, 2016, 76.
61. Katz, L.H., et al. Targeting TGF-beta signaling in cancer. Expert Opin. Ther. Targets 17 (2013), 743–760.
62. Hargadon, K.M., et al. Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells. Immunol. Cell Biol. 94 (2016), 24–38.
63. Ugel, S., et al. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 125 (2015), 3365–3376.
64. Geiger, R., et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167 (2016), 829–842.
65. Cao, Y., et al. L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo. BMC Cancer, 16, 2016, 343.
66. Sakuishi, K., et al. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 32 (2011), 345–349.
67. Saggar, J.K., et al. The tumor microenvironment and strategies to improve drug distribution. Front. Oncol., 3, 2013, 154.
68. Chouaib, S., et al. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene 36 (2017), 439–445.
69. Facciabene, A., et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475 (2011), 226–230.
70. Kumar, V., Gabrilovich, D.I., Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology 143 (2014), 512–519.
71. Sim, G.C., Radvanyi, L., The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 25 (2014), 377–390.
72. Blank, C.U., et al. The “cancer immunogram”. Science 352 (2016), 658–660.
73. Gnjatic, S., et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J. Immunother. Cancer, 5, 2017, 44.
74. Dixon, A.R., et al. Recent developments in multiplexing techniques for immunohistochemistry. Expert Rev. Mol. Diagn. 15 (2015), 1171–1186.
75. Ribas, A., et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170 (2017), 1109–1119.
76. Moesta, A.K., et al. Local delivery of OncoVEXmGM-CSF generates systemic antitumor immune responses enhanced by cytotoxic T-lymphocyte-associated protein blockade. Clin. Cancer Res., 2017, 10.1158/1078-0432.CCR-17-0681 Published online July 13, 2017.
77. Stadler, C.R., et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat. Med. 23 (2017), 815–817.
78. Reiser, J., Banerjee, A., Effector, memory, and dysfunctional CD8(+) T cell fates in the antitumor immune response. J. Immunol. Res., 2016, 2016, 8941260.
79. Gabrilovich, D.I., et al. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12 (2012), 253–268.
80. Spranger, S., et al. Melanoma-intrinsic [bgr]-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.
81. Johnston, P.A., Grandis, J.R., STAT3 signaling: anticancer strategies and challenges. Mol. Interv. 11 (2011), 18–26.
82. Rebe, C., et al. STAT3 activation: A key factor in tumor immunoescape. JAKSTAT, 2, 2013, e23010.
83. Emeagi, P.U., et al. Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy. Gene Ther. 20 (2013), 1085–1092.
84. Ihara, S., et al. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. Cancer Res. 72 (2012), 2990–2999.
85. Yue, C., et al. STAT3 in CD8+ T cells inhibits their tumor accumulation by downregulating CXCR3/CXCL10 Axis. Cancer Immunol. Res. 3 (2015), 864–870.
86. Peng, D., et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527 (2015), 249–253.
87. Nagarsheth, N., et al. PRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell trafficking in colon cancer. Cancer Res. 76 (2016), 275–282.
88. Shields, J.D., et al. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328 (2010), 749–752.
89. Finkin, S., et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat. Immunol. 16 (2015), 1235–1244.
90. Miyasaka, M., Tanaka, T., Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat. Rev. Immunol. 4 (2004), 360–370.
91. Avram, G., et al. The density and type of MECA-79-positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma. Histopathology 63 (2013), 852–861.
92. Martinet, L., et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 71 (2011), 5678–5687.
93. Cipponi, A., et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 72 (2012), 3997–4007.
94. Peske, J.D., et al. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat. Commun., 6, 2015, 7114.
95. Joshi, N.S., et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43 (2015), 579–590.
96. Grabner, R., et al. Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. J. Exp. Med. 206 (2009), 233–248.
97. Ware, C.F., Network communications: lymphotoxins, LIGHT, and TNF. Annu. Rev. Immunol. 23 (2005), 787–819.
98. Tang, H., et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 29 (2016), 285–296.
99. Stack, E.C., et al. Multiplexed tissue biomarker imaging. J. Immunother. Cancer, 4, 2016, 9.
100. Feng, Z., et al. Multispectral imaging of T and B Cells in murine spleen and tumor. J. Immunol. 196 (2016), 3943–3950.
101. Stack, E.C., et al. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 70 (2014), 46–58.
102. Feng, Z., et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J. Immunother. Cancer, 3, 2015, 47.